Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (61-70 of 189) with videos related to

Pageof 19
Sort By:
Haematologica|June 7, 2007
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell linesJérôme Moreaux, Dirk Hose, Michel Jourdan, et al.
British Journal of Haematology|March 21, 2009
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cellsCaroline Bret, Dirk Hose, Thierry Reme, et al.
Blood Cancer Journal|February 17, 2018
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcomeChunyan Gu, Carol Holman, Ramakrishna Sompallae, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myelomaBrigitte Neuber, Isabelle Herth, Claudia Tolliver, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
JCO Precision Oncology|July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell TransplantationManuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
Pageof 19

Showing results (61-70 of 189) with videos related to

Sort By:
Pageof 19
Haematologica|June 7, 2007
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell linesJérôme Moreaux, Dirk Hose, Michel Jourdan, et al.
British Journal of Haematology|March 21, 2009
Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cellsCaroline Bret, Dirk Hose, Thierry Reme, et al.
Blood Cancer Journal|February 17, 2018
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcomeChunyan Gu, Carol Holman, Ramakrishna Sompallae, et al.
Leukemia|November 13, 2019
Cytogenetic subclone formation and evolution in progressive smoldering multiple myelomaMaximilian Merz, Thomas Hielscher, David Schult, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myelomaBrigitte Neuber, Isabelle Herth, Claudia Tolliver, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
JCO Precision Oncology|July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell TransplantationManuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
Pageof 19